Survey Finds Athletes Using More Cannabinoids, ICBC Reports

What the survey reported, and what it left out

The International Cannabis Business Conference reported on Oct. 31 that athletes are using cannabinoids at growing rates, but the public summary doesn't show how the data was gathered.

At publication, the material available to CannIntel included only the headline and the publisher listing. It didn't include a sample size, the sports or competitive levels surveyed, the share of respondents using any given product, or the group that ran the poll.

That gap matters. A survey of weekend marathoners and a survey of professional rosters describe two different markets. They carry different risk, too.

So the direction is the news. The magnitude is unknown. "Increasingly" is a trend claim, and a trend needs a baseline year before it means anything.

Cannabinoids isn't one product, and the rules don't treat them alike

The word "cannabinoids" covers THC, CBD and a growing list of minor compounds, and anti-doping and league rules draw sharp lines between them.

Under the World Anti-Doping Agency's Prohibited List, natural and synthetic cannabinoids are banned in competition, with one carve-out by name: cannabidiol. It doesn't carve out CBN, CBG or anything else. Athletes who treat every non-THC compound as safe are making an assumption the list doesn't make for them.

Pro leagues have moved faster than international sport. The NFL stopped suspending players for positive cannabis tests under its 2020 labor agreement. Big change.

Which is why the survey's missing detail is so frustrating, because an athlete rubbing CBD cream on a sore knee and an athlete vaping THC the night before a game are in very different positions, yet a single "uses cannabinoids" figure can fold both into one number and leave readers to guess at the difference.

The operator lens: the athlete customer is the least forgiving one

For brands and retailers, a growing athlete customer base raises the stakes on batch testing, labeling and recovery claims.

A positive test can cost an athlete eligibility or income. For that customer, trace THC in a CBD product isn't a rounding error. It's a career risk, and it lands on the brand's reputation.

Claims are the other exposure. The FDA has not cleared CBD for sale as a dietary supplement, and "recovery" is exactly the kind of language that draws scrutiny when it's attached to an ingestible. Marketing to athletes without that discipline is a bad bet.

Operators eyeing this segment should be able to answer three questions before they pitch a single team or gym:

• Does every batch have a certificate of analysis showing what's in the product, including THC?
• Are performance and recovery claims reviewed against FDA rules?
• Is there a clear separation between products for in-competition and off-season use?

Here's the editorial read: a bigger athlete market is real money for the right operators, but it rewards compliance more than it rewards branding. The brands with documentation will keep the customers. The ones with only a celebrity endorsement won't.

What to watch: methodology, not the headline

The survey's methodology, not its headline, will decide whether this is a market signal or a marketing one.

Conference-hosted data can be useful. It can also be built to sell the next ticket. Neither is disqualifying, but readers deserve to know which they're looking at. For full background on how this story fits the larger debate, see the CannIntel topic hub on athletes and cannabinoids.

The next signal: whether the International Cannabis Business Conference publishes the full survey instrument, sample size and respondent breakdown. Until it does, the trend is plausible and the number is missing. Any product-level claim built on it is unproven.